Publications

Goodman SJ, Haver C, Snow SJ, Eftim S, Bergeron JG, Vincent-Hall TD. Evaluating the non-cancer health outcomes associated with exposure to jet fuels: A fit-for-purpose systematic literature review. Abstract 3135, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Allen B, Heitz E, Goodman S, Freedman A, Miller S, Haver C, Snow S, Weinberger K, et al. Understanding the cancer outcomes associated with exposure to jet fuels: A fit-for-purpose systematic literature review. Abstract 4676, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Sakolish C, Moyer H, Barlow N, Roe H, Tsai H, Ford L, Bajaj P, Villenave R, et al. Microphysiological systems as predictive tools for kidney nephrotoxicants: A comparison across four platforms. Abstract 3216, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Moyer H, Vergara L, Sakolish C, Stephan C, Barlow N, Roe H, Hewitt P, Villenave R, Rusyn I. Comparative analysis of drug permeability and toxicity in intestinal segment-specific membrane-based barrier model using Caco-2 and human jejunal and duodenal enteroid-derived cells. Abstract 3217, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Bogar L, Yale K, Allen L, Burns A. Airborne silica from bentonite clay cat litter: An evaluation of potential non-occupational exposure and respiratory health risks. Abstract 4760, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Schaefer H. An introduction to evidence integration. Abstract 1333, Society of Toxicology 64th Annual Meeting, Orlando, FL, 2025

Jacobellis M, Garcia M, Bain L, Pearce J, Hunt K, Baldwin W. Disruption of energy homeostasis by chemical mixtures containing persistent pollutants in HepG2 and C2C12 cells. Abstract 4564, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Reynolds JI, Yelleti A, Johnson BP. Bridging data gaps in sonic hedgehog signaling: A novel microphysiological model approach. Abstract 3234, Society for Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Covell LT, Han AA, Blanchette AD, Madl AK. Comparison of harmful and potentially harmful constituents (HPHC) and associated excess lifetime cancer risks (ELCR) across oral nicotine products. Abstract 4911, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Blanchette AD, Donnell MT, Covell LT, Madl AK. A machine learning-based framework for predicting carcinogenic potencies for nitrosamine compounds. Abstract 4040, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Wood LA, Langton CR, Donnell MT, Covell LT, Blanchette A, Keeton K, Benson SM. Asbestos exposure and para-testicular mesothelioma. Abstract 4586, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Wikoff D. Use cases of strategic application of ML/AI in the risk assessment process. Toxicology Forum 2025 Winter Meeting, Raleigh, NC, February 2025.

Wikoff D. Pragmatic solutions for better using evidence-based methods to integrate observational data in food safety assessments. Toxicology Forum 2025 Winter Meeting, Raleigh, NC, February 2025.

Schaefer H. Cadmium–Initiatives to reduce dietary exposure. Society for Risk Analysis Annual Meeting, Austin, TX, 2024.

Haselkorn T, Hughes W, Schara-Schmidt U, Lennox A, Roca A, Miller B, Jensen I, Solomon F, et al. 2024. Abstract PCR257: Real-world impact of x-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. Value in Health 27(12-Sup):S557; doi: 10.1016/j.val.2024.10.3499.

Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693, ISPOR Europe 2024. Value in Health 27(12 Sup):S191; doi: 10.1016/j.jval.2024.10.973. Barcelona, November 2024.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. The cost-effectiveness of atidarsagene autotemcel (ARSACEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain. ISPOR Europe 2024, November 2024.

Haselkorn T, Roca A, Miller B, Jensen I, Solomon F, Sanchez-de la Rosa R, Picart JM, Nascimento A. A real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in Spain. Presented at LXXVI Reunion Annual de la Sociedad Espanola de Nurologica, Valencia, Spain, 19–23 November 2024.

Gauthier A, Bare J, Kramer M. Tools and tips for exposure assessment throughout the product development life cycle. Education session, PSX 2024, Annual Conference of the Product Stewardship Society, Denver, CO, October 2024.

Kelsh M, Bylsma LC, Jiang X, Movva N, Sacks NC. To be an orphan disease or not to be: An evaluation of prevalence estimates for cancers near the orphan status threshold and implications for orphan drug planning. International Society for Pharmacoepidemiology, 40^th Annual Meeting, Berlin, Germany, August 2024.